Scientists develop first bone marrow model that supports human stem cells

byUniversity of GlasgowSchematic of the bone marrow (BM) niche microenvironment. Credit:Nature Communications(2024). DOI: 10.1038/s41467-024-50054-0Scientists have created the first

Updated on: August 03,2024

Scientists develop first bone marrow model that supports human stem cells

byUniversity of GlasgowSchematic of the bone marrow (BM) niche microenvironment. Credit:Nature Communications(2024). DOI: 10.1038/s41467-024-50054-0Scientists have created the first

Updated on:August 03,2024

Deaths from advanced lung cancer have dropped significantly since immunotherapy became standard-of-care

byWileyCredit: Unsplash/CC0 Public DomainSince the first immunotherapy drug to boost the body's immune response against advanced lung cancer was introduced in the United States in 2015, surv

Updated on: August 27,2024

Deaths from advanced lung cancer have dropped significantly since immunotherapy became standard-of-care

byWileyCredit: Unsplash/CC0 Public DomainSince the first immunotherapy drug to boost the body's immune response against advanced lung cancer was introduced in the United States in 2015, surv

Updated on:August 27,2024

Relapse Following CAR T-cell Therapy Linked to Poor OS in Relapsed/Refractory Myeloma

August 27, 2022Lisa AstorRelapse following treatment with BCMA-directed CAR T-cell therapy was associated with poor survival outcomes in patients with relapsed/refractory multiple myeloma.Multiple Mye

Updated on: October 24,2023

Relapse Following CAR T-cell Therapy Linked to Poor OS in Relapsed/Refractory Myeloma

August 27, 2022Lisa AstorRelapse following treatment with BCMA-directed CAR T-cell therapy was associated with poor survival outcomes in patients with relapsed/refractory multiple myeloma.Multiple Mye

Updated on:October 24,2023

Ultrafine particles can change defense against lung cancer

by Graciela Gutierrez,Baylor College of MedicinenCB accelerates NSCLC development and metastasis in mice. (A) Schematic diagram of nCB exposure in Pts4d/dmice. Three-month-old Pts4d/d&nbsp

Updated on: December 19,2023

Ultrafine particles can change defense against lung cancer

by Graciela Gutierrez,Baylor College of MedicinenCB accelerates NSCLC development and metastasis in mice. (A) Schematic diagram of nCB exposure in Pts4d/dmice. Three-month-old Pts4d/d&nbsp

Updated on:December 19,2023

Curbing blood cancers by teaching immune cells to kill mutant stem cells

by Nancy Fliesler,Children's Hospital BostonROS and TLR3 signaling mediates the "eat-me" and "don't eat me" signals that determine stem cell clonal selection by macro

Updated on: October 24,2024

Curbing blood cancers by teaching immune cells to kill mutant stem cells

by Nancy Fliesler,Children's Hospital BostonROS and TLR3 signaling mediates the "eat-me" and "don't eat me" signals that determine stem cell clonal selection by macro

Updated on:October 24,2024

Using a machine learning algorithm with cancer methylation signatures to diagnose colorectal cancer

by Bob Yirka , Medical XpressCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0A team of researchers affiliated with a large number of institutions in China has used a m

Updated on: December 20,2023

Using a machine learning algorithm with cancer methylation signatures to diagnose colorectal cancer

by Bob Yirka , Medical XpressCancer—Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0A team of researchers affiliated with a large number of institutions in China has used a m

Updated on:December 20,2023

Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer

byAmerican Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainThe next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compar

Updated on: December 21,2023

Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer

byAmerican Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainThe next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compar

Updated on:December 21,2023

Study of rare cancer identifies patients at highest risk of metastasis and those who would respond to immunotherapy

byThe Spanish National Cancer Research CentreCNIO researchers Bruna Calsina (left) and Mercedes Robledo. Credit: Laura M. Lombardía, CNIOPheochromocytoma is a rare tumor, with an incidence of th

Updated on: December 23,2023

Study of rare cancer identifies patients at highest risk of metastasis and those who would respond to immunotherapy

byThe Spanish National Cancer Research CentreCNIO researchers Bruna Calsina (left) and Mercedes Robledo. Credit: Laura M. Lombardía, CNIOPheochromocytoma is a rare tumor, with an incidence of th

Updated on:December 23,2023

CAR T cell therapy for T cell lymphoma shows promise in phase I trial

by Molly Chiu,Baylor College of MedicineCredit: Pixabay/CC0 Public DomainResearchers at the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital, and Hou

Updated on: January 26,2024

CAR T cell therapy for T cell lymphoma shows promise in phase I trial

by Molly Chiu,Baylor College of MedicineCredit: Pixabay/CC0 Public DomainResearchers at the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital, and Hou

Updated on:January 26,2024

Single-cell 'atlas' reveals origin of an aggressive brain tumor

byCincinnati Children's Hospital Medical CenterChartshows that mice with reduced activity of either the SOX11 or HNRNOH1 genes had longer survival times when induced to develop medullo

Updated on: December 20,2023

Single-cell 'atlas' reveals origin of an aggressive brain tumor

byCincinnati Children's Hospital Medical CenterChartshows that mice with reduced activity of either the SOX11 or HNRNOH1 genes had longer survival times when induced to develop medullo

Updated on:December 20,2023

New clue discovered as to how and why cancer cells spread

by Gillian Rutherford,University of AlbertaViscosity enhances cell migration and promotes an ARP2/3-mediated dense actin network at the leading edge.a,b, Speeds of MDA-MB-231 cells (a) and

Updated on: December 22,2023

New clue discovered as to how and why cancer cells spread

by Gillian Rutherford,University of AlbertaViscosity enhances cell migration and promotes an ARP2/3-mediated dense actin network at the leading edge.a,b, Speeds of MDA-MB-231 cells (a) and

Updated on:December 22,2023

Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in some breast cancer

byScience China PressThe CDK4/6 inhibitors-resistant breast cancer cells expressed more Cyclin D1 and CDK4 proteins than the parental cells (Upper left). PI3K pathway was hyper-activated in the

Updated on: December 23,2023

Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in some breast cancer

byScience China PressThe CDK4/6 inhibitors-resistant breast cancer cells expressed more Cyclin D1 and CDK4 proteins than the parental cells (Upper left). PI3K pathway was hyper-activated in the

Updated on:December 23,2023